The information contained in this section of the site is intended for US healthcare professionals only.
Are you a US healthcare professional?
Severe and persistent pain is pain that lasts longer than 6 months. It can impact daily activities, sleep, even relationships and work.
Treatment for severe and persistent pain is not as simple as finding a one-size-fits-all solution. There are many treatment options to help severe and persistent pain. You and your healthcare provider will work together to determine what works best for you.
You and your healthcare provider may decide you need to move beyond your current treatment if your medications or therapies are not reducing your pain level enough, you are losing sleep because of pain, you are frequently using a short-acting opioid, or you need treatment for severe and persistent pain for an extended treatment period.
BELBUCA is a strong prescription pain medicine (buprenorphine) that contains an opioid (narcotic) that is used to manage severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine when other pain medicines do not treat your pain well enough or you cannot tolerate them.
BELBUCA is a long-acting opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death. Not to be taken on an “as needed” basis.
BELBUCA contains a medication called buprenorphine. Buprenorphine is a long-acting opioid that stays in your system longer than short-acting opioids. This means BELBUCA can be taken every 12 hours, instead of every 4 to 6 hours like many short-acting opioids.
Until your body adjusts to treatment, you may experience side effects like nausea, constipation, headache, vomiting, dizziness, or sleepiness. Your healthcare provider may adjust your dose to provide pain relief or to help minimize any side effects. Do not change your dose or stop taking BELBUCA without talking to your healthcare provider.
The BELBUCA buccal film technology helps the medicine, buprenorphine, get into your body more quickly than when it is swallowed. When swallowed, buprenorphine is significantly less effective at treating your pain. Do not chew, swallow, snort, or inject BELBUCA. This will result in uncontrolled delivery of buprenorphine and may cause you to overdose and die.
BELBUCA has 7 dose strengths that will help you and your healthcare provider find your optimal dose. An optimal dose is the amount that provides the relief you need while minimizing side effects. It may take a few adjustments to find your optimal dose, so remember to talk to your doctor frequently.
Call your healthcare provider if the dose you are using does not control your pain. Do not stop using BELBUCA without talking to your healthcare provider.
Before you begin, make sure the inside of your mouth is moist, either by using your tongue or by rinsing your mouth with water. Be sure your fingers are clean and dry. To apply BELBUCA, just peel, place, and press.
Peel and tear open the package to carefully remove the film. Place the film on your finger. Press the yellow side against the inside of your cheek. It may take a few times to get accustomed to using BELBUCA.
Do not apply BELBUCA if the package seal is broken or the film is cut, damaged, or changed in any way.
BELBUCA should be applied to the middle of the inside of your cheek. Do not place the film too high or too far back on your cheek. Avoid applying the film to areas of your mouth with any open sores or lesions.
Do not eat or drink until the buccal film has completely dissolved. After applying BELBUCA, you can speak and swallow normally while the film is dissolving, usually within 30 minutes—just do not do anything that would move the buccal film in your mouth.
While BELBUCA is adhered to the inside of your cheek, you may taste a mild peppermint flavor. As it dissolves, it is normal for the texture of the film to change.
BELBUCA works by sticking to the inside of your cheek and then dissolving completely—usually within 30 minutes. Leave BELBUCA on the inside of your cheek until fully dissolved. If you chew or swallow the buccal film, it may not be as effective or may cause choking, overdose, or death. As such, be careful not to chew or swallow the film.
Dispose of expired, unwanted, or unused BELBUCA by removing the BELBUCA film from the foil packaging, and promptly flushing down the toilet (if a drug takeback option is not readily available). Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.
The cost of BELBUCA varies based on your insurance plan. BELBUCA offers copay assistance to eligible commercially insured patients and is dedicated to helping patients access the medication they need. Restrictions apply. Please see eligibility criteria on the back of the card.
Visit our Savings page to download a Belbuca copay card.
Please see full Prescribing Information, including Boxed Warning on Addiction, Abuse, and Misuse, and other serious risks. Speak to your healthcare provider if you have questions about BELBUCA.
APPROVED USE
*BELBUCA® (buprenorphine buccal film) CIII is:
A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage severe and persistent pain that requires an extended treatment period with a daily opioid pain medicine when other pain medicines do not treat your pain well enough or you cannot tolerate them.
A long-acting opioid pain medicine that can put you at risk for overdose and death. Even if you take your dose correctly as prescribed, you are at risk for opioid addiction, abuse, and misuse that can lead to death.
Not to be taken on an “as needed” basis.
IMPORTANT SAFETY INFORMATION ABOUT BELBUCA®
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA
Addiction, Abuse, and Misuse
BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing BELBUCA, and monitor regularly for these behaviors and conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and poses a significant risk of overdose and death.
Accidental Exposure
APPROVED USE
*BELBUCA® (buprenorphine buccal film) CIII is:
Important information about BELBUCA:
Do not use BELBUCA if you have:
Before taking BELBUCA, tell your healthcare provider if you have a history of:
IMPORTANT SAFETY INFORMATION about BELBUCA®
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF BELBUCA
Addiction, Abuse, and Misuse
BELBUCA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing BELBUCA, and monitor regularly for these behaviors and conditions.
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with use of BELBUCA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of BELBUCA are essential. Misuse or abuse of BELBUCA by chewing, swallowing, snorting, or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and poses a significant risk of overdose and death.
Accidental Exposure
Accidental exposure to even one dose of BELBUCA, especially in children, can result in a fatal overdose of buprenorphine.
Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants
Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of BELBUCA and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
Neonatal Opioid Withdrawal Syndrome (NOWS)
If opioid use is required for an extended period of time in a pregnant woman, advise the patient of the risk of NOWS, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery.
Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription.
Tell your healthcare provider if you are:
When taking BELBUCA:
While using BELBUCA DO NOT:
The possible side effects of BELBUCA are:
Get emergency medical help or call 911 right away if you have:
These are not all the possible side effects of BELBUCA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to dailymed.nlm.nih.gov.
Please see full Prescribing Information, including Boxed Warning on Addiction, Abuse, and Misuse, and other serious risks, and Medication Guide, or speak to your healthcare provider if you have questions about BELBUCA.